公开(公告)号：CA3130735A1

公开(公告)日：2020-08-06

申请号：CA3130735

申请日：2020-01-30

Applicant: SANIFIT THERAPEUTICS S A

Inventor： BASSISSI MOHAMAD FIRAS ,  SALCEDO ROCA CAROLINA ,  PERELLO BESTARD JOAN ,  FERRER REYNES MIQUEL DAVID ,  PEREZ FERRER MARIA DEL MAR

IPC: A61K31/6615 ,  A61P9/10 ,  A61P13/12

Abstract: The present invention relates to inositol phosphates, analogs, derivatives and pharmaceutically acceptable salts thereof, for use in increasing tissular perfusion and/or oxygenation in a subject in need thereof, in particular peripheral arterial disease. The present invention also relates to pharmaceutical compositions comprising said inositol phosphates, analogs, derivatives and pharmaceutically acceptable salts thereof, and their use in increasing tissular perfusion and/or oxygenation and for treating and preventing peripheral arterial disease.

公开(公告)号：CA3156023A1

公开(公告)日：2021-05-20

申请号：CA3156023

申请日：2020-11-10

Applicant: SANIFIT THERAPEUTICS S A

Inventor： PERELLO BESTARD JOAN ,  SALCEDO ROCA CAROLINA ,  FERRER REYNES MIQUEL DAVID

IPC: A61K31/6615 ,  A61K45/06 ,  A61P9/10 ,  A61P9/14

Abstract: The present invention relates to compounds, pharmaceutical compositions, combined preparations, and dosage regimens for treating, inhibiting the progression, and preventing cardiovascular calcification, and in particular, coronary calcification, aortic artery calcification, and aortic valve calcification comprising inositol phosphates. In a particular aspect the disclosure provides a dosage regimen for treating, inhibiting the progression, or preventing cardiovascular calcification comprising the administration of about 200 mg to about 700 mg of myo-inositol hexaphosphate per administration.

公开(公告)号：CA3113377A1

公开(公告)日：2020-04-16

申请号：CA3113377

申请日：2018-10-11

Applicant: SANIFIT THERAPEUTICS S A

Inventor： PERELLO BESTARD JOAN ,  SALCEDO ROCA CAROLINA ,  CANALS HAMANN ANA-ZERALDA

IPC: A61K31/6615 ,  A61K9/00 ,  A61K31/661 ,  A61K45/06 ,  A61P17/02 ,  A61P43/00

Abstract: The present disclosure related to compositions, methods, dosages, dosage regimens, articles of manufacture and kits for the treatment and/or prevention ectopic calcifications, and in particular cutaneous calcifications such as calciphylaxis calcifications comprising inositol phosphate, inositol phosphate analogs, inositol phosphate derivatives, or combinations thereof. In a particular aspect the disclosure provides a dosage regimen to treat calciphylaxis comprising the administration of 6 mg/kg to 9 mg/kg daily doses of myo-inositol hexaphosphate, three times a week, for at least 1 to 8 months.